JPRN-jRCT2080222256未知3 期
A multi-center, open label study of subcutaneous secukinumab in prefilled syringes as mono- or co-therapy to assess the efficacy, safety and tolerability up to 52 weeks in Japanese subjects with generalized pustular psoriasis
ovartis Pharma K.K.0 个研究点开始时间: 2013年10月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •*At baseline, presence of GPP classified on the basis of the criteria for diagnosis of GPP by Japanese Dermatological Association (JDA)
- •*At baseline, erythema area with pustule more than or equal to 10%
排除标准
- •*Erythrodermic, guttate psoriasis, or subcorneal pustular dermatosis at screening.
- •*At baseline, total score of JDA severity index for GPP more than or equal to 14
- •*Drug-induced psoriasis
- •*Ongoing use of prohibited psoriasis treatments.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
相似试验
未知
4 期
A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine APlaque PsoriasisJPRN-jRCT1080222997ovartis Pharma K.K.
进行中（未招募）
不适用
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple MyelomaEUCTR2008-000952-28-GBJanssen-Cilag International NV (JCI)216
进行中（未招募）
1 期
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple MyelomaThe subject population comprises adult male and female subjects with multiple myeloma that has relapsed or progressed after prior systemic antineoplastic therapy, presence of measurable secretory disease, Karnofsky performance status score greater than or equal to 70%, and clinical hematology and chemistry laboratory values that meet predefined criteria.MedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000952-28-FRJanssen-Cilag International NV (JCI)
进行中（未招募）
不适用
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple MyelomaThe subject population comprises adult male and female subjects with multiple myeloma that has relapsed or progressed after prior systemic antineoplastic therapy, presence of measurable secretory disease, Karnofsky performance status score greater than or equal to 70%, and clinical hematology and chemistry laboratory values that meet predefined criteriaMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000952-28-BEJanssen-Cilag International NV (JCI)216
尚未招募
3 期
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple MyelomaNL-OMON32310Janssen-Cilag10